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S U P P L E M E N T A R T I C L E
Management of Cytomegalovirus Infection
and Disease after Solid-Organ Transplantation
Wim van der Bij1 and Rudolf Speich2
1Department of Clinical Immunology, University Hospital, Groningen, The Netherlands; and 2Department of Internal Medicine, University Hospital,
Zurich, Switzerland
Cytomegalovirus (CMV) continues to be a cause of substantial morbidity and death after solid-organ trans-
plantation. There are 3 major consequences of CMV infection: CMV disease, including a wide range of clinical
illnesses; superinfection with opportunistic pathogens; and injury to the transplanted organ, possibly enhancing
chronic rejection. This article discusses the considerable progress that has been made in elucidating risk factors
for CMV disease, in the rapid detection of CMV in clinical specimens, and in the use of antiviral chemotherapy
and immunoglobulin to prevent and treat CMV disease after solid-organ transplantation.
CLINICAL CONTEXT AND DEFINITIONS
Cytomegalovirus (CMV) is a ubiquitous virus; the se-
ropositivity in the population ranges worldwide from
40% to 190%. Because of its opportunistic behavior
under immunosuppression, active CMV infections gen-
erally have a large impact on the clinical course of organ
transplant recipients. The negative influence of CMV
on the results of transplantation is beyond any doubt.
Depending on donor-recipient (D/R) match, diag-
nostic techniques, and mode and magnitude of im-
munosuppression, the onset of the majority of active
CMV infections after solid-organ transplantation
ranges from 2 weeks to several months after transplan-
tation. Active CMV infection occurs in 30%–75% of
the transplant recipients at risk, with a mortality rate
of ∼5%, even at present. Serious and often fatal sec-
ondary infections (especially fungal) are of great con-
cern. At greatest risk are patients with a D/Rmatch,
patients undergoing lympholytic induction or rejection
therapy, and patients with previous or concomitant
(super-)infections. Whereas the incidence of CMV dis-
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ease is 8%–35% in kidney, heart, and liver transplant
recipients, its frequency is considerably higher in pan-
creas or kidney-pancreas (50%) and lung or heart-lung
transplant recipients (50%–80%).
A number of effects and sequelae have been linked
to (active) CMV infection, such as CMV-related symp-
toms and organ dysfunction; contribution to the so-
called net state of immunosuppression after organ
transplantation; the clinical observation of a mutual
influence between CMV infection and acute transplant
rejection; a possible role of CMV in the development
of chronic transplant dysfunction, such as accelerated
coronary atherosclerosis after heart transplantation,
vanishing bile duct syndrome after liver transplanta-
tion, and bronchiolitis obliterans syndrome after lung
transplantation; and a role as an independent risk factor
in the development of posttransplant lymphoprolifer-
ative disease.
The following definitions are often used with regard
to CMV infection: latency: carriership of the CMV ge-
nome in a seropositive individual with a primarily low-
grade, persistent infection, but without signs of active
viral replication; active infection: a state of viral repli-
cation characterized by the detectable presence of CMV
in blood or organs and/or a significant rise in CMV-
specific antibodies; primary infection: active infection in
a previously nonimmune seronegative individual (e.g.,
in a CMV-seronegative recipient of an organ from a
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seropositive donor); secondary infection: active infection in an
already seropositive individual (e.g., a reactivation in a CMV-
seropositive organ transplant recipient); CMV disease or syn-
drome: clinical expression of active infection, ranging from gen-
eral discomfort, fever, myalgia, or arthralgia to organ
involvement (hepatitis, pneumonitis, gastroenteritis, colitis, en-
cephalitis, and so forth) or a severe, often life-threatening, wast-
ing disease.
Most available information, based on both clinical experience
and reports from the literature, is derived from the clinical
context of immunosuppression today (i.e., varying combina-
tions of cyclosporine or tacrolimus, azathioprine, prednisolone,
antilymphocyte antibody preparations, or OKT3). Nevertheless,
since (1) more “rejection-sensitive” types of transplantation are
being performed (e.g., lung transplantation) or introduced (e.g.,
bowel transplantation), (2) chronic transplant dysfunction is
still a major impediment to long-term graft and patient sur-
vival, and (3) more potent immunosuppressant drugs are be-
coming available, there will be an inevitable tendency to in-
tensify immunosuppression, with its inherently increased risk
of opportunistic infections. This development obviously will
influence our considerations and recommendations with regard
to diagnosis and therapy of CMV. The practical consequence
is that reliable and efficient diagnostic tools and effective ther-
apy will become increasingly important. Intensification of anti-
microbial, especially prophylactic, measures will also be a logical
consequence.
The goal of CMV management is to prevent or to treat CMV
disease with a minimum of side effects. On the basis of the
differential susceptibility of the respective organ transplants to
rejection and infection, groupings of transplants into low risk
(kidney), intermediate risk (liver, heart, pancreas), and high
risk (lung, intestine, bone marrow) for CMV infection may be
used arbitrarily. Apart from the type of transplant, certain clin-
ical states of increased immunosuppression (e.g., during the
administration of lympholytic therapy or intensified mainte-
nance immunosuppression) will add to the “a priori” risk of
serious CMV infection. Efficacy and toxicity of antiviral mea-
sures should be proportional to this risk.
Thus, major determinants for the management of CMV are
the type of organ transplantation, the type and extent of im-
munosuppression, the possibility and/or necessity of sero-
matching, the availability of tools for rapid and early diagnosis
and monitoring, and the qualities of the antiviral compounds.
DIAGNOSIS
Determination of the CMV serostatus of donor and recipient
is important in anticipation of the type and thus the clinical
risk of active CMV infection. CMV-DNA [1] and CMV-RNA
[2] could be demonstrated in 125% of seronegative blood do-
nors. This underscores that a sensitive serological technique is
mandatory for determination of the CMV serostatus, mainly
to prevent misjudgment of seropositivity of the donor (false
seronegativity).
On the other hand, misjudgment of the seronegative donor
(false seropositivity) may lead to erroneous risk stratification
after transplantation. Techniques such as ELISA, radioimmuno-
assay, or indirect hemagglutination assay [3–5] are superior to
obsolete tests such as complement fixation test or passive hem-
agglutination assay.
Recommendation: Efficient and sensitive serological assays
(preferably ELISA or indirect hemagglutination assay) should be
used to determine the serostatus of donor and recipient (A-II).
Serological techniques are of limited value for the diagnosis
of active infection after transplantation, and certainly during
increased intensity of immunosuppression. Significant antibody
rises simply come (too) late, and tests for IgM often remain
negative. Those patients showing increases of CMV-specific
antibody without viremia, antigenemia, DNAemia, or tissue
invasion represent the mildest cases.
CMV viruria is a classical marker of CMV infection but may
be present for years. For this reason, it is not the diagnostic
measure of choice for most centers. In one report [6], however,
quantitation of viral DNA in urine by quantitative PCR (qPCR)
showed a correlation between virus load and the clinical ex-
pression of disease.
Clinically relevant CMV infection after organ transplantation
is associated with viremia [7] and/or organ infiltration. For this
reason, active CMV infection is most efficiently diagnosed and
followed by a technique that allows rapid, early, sensitive, and
specific determination of the presence of the virus or virus
products in blood or the organ in question. Culture and rapid
shell vial assay methods of detecting CMV [8] are generally less
sensitive, more elaborative, and more time-consuming than are
methods to detect CMV, antigenemia, or viral nucleic acids in
blood (preferentially by qPCR) and immunohistochemical
techniques, which were developed and introduced during the
1990s.
Detection of CMV-pp65 in peripheral blood leukocytes (anti-
genemia) has proved to be superior to tests based on virus
isolation [9–11]. The test is applicable in all transplant recip-
ients. In CMV disease, antigenemia runs parallel with the period
of symptoms. An additional advantage is the possibility to
quantify the virus load and the subsequent link to preemptive
therapy [12]. Varying thresholds (10/50,000–100/200,000 pos-
itive circulating peripheral blood leukocytes) for therapeutic
intervention have been suggested. Standardization of the tech-
nique is needed [13], because of interlaboratory variation with
respect to assay sensitivity.
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DNA hybridization and, especially, PCR [14–16] are now
being implemented for early detection of DNA/RNAemia and
thus the diagnosis of active infection after transplantation.
These assays generally have a sensitivity and specificity for the
diagnosis of active infection of 180% and diagnose active in-
fection 1–3 weeks before conventional tools or CMV disease.
From a practical and technical point of view, there is con-
siderable variation between laboratories in choice of blood
components, primers, and amplification schemes. For instance,
the buffy coat fraction (mainly the polymorphonuclear cells)
is reported to carry the highest copy numbers. The mononu-
clear cell fraction remains positive long after treatment and is
frequently positive during latency [17]; however, an earlier
study [15] suggested that PCR of plasma samples after bone
marrow or kidney transplantation may prove useful in diag-
nosis and therapy guidance. A report [18] on PCR primers for
the detection of CMV-DNAemia suggested that a primer di-
rected to the HindIII-X region was clinically useful for early
diagnosis (sensitivity 100% for symptomatic disease, but spec-
ificity disappointingly low at 45%).
Comparative studies of CMV antigenemia detection versus
PCR for DNAemia [19–24] in a variety of organ transplanta-
tions permit the following conclusions. Both assays have a con-
cordancy of 80%. Both assays are superior to other tests with
respect to early diagnosis (PCR slightly earlier than antigene-
mia), frequently (in 180% of cases) detecting CMV 0–2 weeks
before onset of disease. Because of the possibility of enumer-
ation of CMV-pp65 cells, it seems that, with respect to mon-
itoring of active infection and clinical disease, antigenemia de-
tection is superior to the classical PCR. Further development
of qPCR will probably equalize this difference. A final difference
between both assays is technical in nature: although CMV anti-
genemia detection is probably less demanding than PCR, the
latter can be implemented in the array of routine PCRs. Inter-
center quality control and standardization are relevant for both
assays.
Recommendation: Detection tests for CMV antigenemia
or DNA/RNAemia (especially qPCR) are methods of choice for
diagnosis and monitoring of active CMV infection after organ
transplantation (A-II).
SURVEILLANCE
Surveillance is a prerequisite for preemptive treatment, based
on laboratory parameters, for those patients at increased risk
of CMV disease. CMV antigenemia testing or qPCR is useful
for surveillance of active infection (A-II). In some centers, how-
ever, virus detection in urine samples is also advocated for
surveillance [25].
PREVENTION
A number of studies have demonstrated effects of vaccination
of volunteers and hemodialysis patients with CMV. In one such
study, live, attenuated Towne strain of CMV was administered
to CMV-seronegative patients on hemodialysis. In case of trans-
plantation of a kidney from a seropositive donor, the incidence
of primary infection was not influenced, but the infection showed
a more benign clinical course [26]. Active immunization, how-
ever, has not reached broad clinical application. Avoidance of
primary infection, whenever possible, is preferred, because this
type of infection is the most harmful for the transplant recipient
in terms of morbidity and death. The logical approach is to match
seronegative donors to seronegative recipients with respect to
both the transplanted organ and the use of blood and blood
components; however, the CMV-induced morbidity and mor-
tality rates should be weighed against the degree of donor short-
age in the respective organ transplantation.
Recommendation: Seromatching for CMV is strongly ad-
vised in cases of lung and intestinal transplantation (A-II).
TREATMENT
Types of treatment are the following [27]: therapeutic use: treat-
ment based on the presence of established infection; prophy-
lactic use: use of antimicrobial therapy from the earliest possible
moment; preemptive use: antimicrobial therapy before clinical
signs of infection, guided by a clinical or epidemiological char-
acteristic or a prospective surveillance technique; deferred ther-
apy: initiation of therapy after onset of disease, guided by a
fixed laboratory or other marker.
ANTIVIRAL THERAPY (OF ESTABLISHED
DISEASE)
Therapy with ganciclovir (Gcv) was implemented at a time
when therapy was desperately needed, without formal random-
ized, controlled studies. In therapeutic use in the classical sense
(i.e., at the onset of clinical disease), iv Gcv is the cornerstone
of therapy. Anti-CMV hyperimmunoglobulin preparations are
useful adjuncts in seronegative recipients of seropositive organs;
foscarnet can be considered as rescue therapy (because of its
inherent toxicity) in case of Gcv failure.
Recommendation: In the therapeutic setting of CMV dis-
ease, iv Gcv is the drug of choice. In the case of clinical non-
responsiveness or signs of Gcv resistance, a switch to foscarnet
is advised (A-II).
ANTIVIRAL PROPHYLAXIS
Studies on anti-CMV prophylaxis show a large variety in many
aspects: type of transplantation or subgroup within that par-
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ticular transplantation, type or combination of compounds,
study setup, and end points.
Anti-CMV Hyperimmunoglobulins
Randomized, placebo-controlled trials to determine the efficacy
of anti-CMV hyperimmunoglobulin preparations have been
conducted in the setting of liver [28, 29] and kidney trans-
plantation [30]. Taken together, this prophylaxis significantly
lowered the rate of (severe) CMV disease (A-I). Except for
patients with a D/R match, the risk of CMV disease was
significantly lower even after OKT3 treatment [29]. A smaller
placebo-controlled study of kidney transplantation [31] showed
an effect of anti-CMV hyperimmunoglobulin in patients with
a D/R match only after administration of lympholytic re-
jection therapy (B-II). With regard to passive immunization
with anti-CMV hyperimmunoglobulin preparations, it is not
known which CMV antigen(s) and, consequently, which CMV-
specific antibodies are immunorelevant. Because it is a biolog-
ical product, product-to-product and also batch-to-batch var-
iations are to be expected. The product is expensive, although
probably cost-effective [32].
Gcv
The prophylactic application of Gcv is the main focus of a
growing number of studies. In a concise meta-analysis of a
number of randomized, controlled trials (A-I) [33], iv or oral
Gcv or high-dose oral acyclovir (Acy) was compared with pla-
cebo or no treatment on the occurrence of CMV infection or
disease in patients after solid-organ (kidney, heart, or liver)
transplantation. Prophylactic treatment with either Gcv or Acy
in both kidney and liver transplant recipients resulted in sig-
nificant risk reduction for CMV infection and disease. For heart
transplant recipients (donor or recipient seropositive), a sig-
nificant reduction of disease was also calculated. Subgroup anal-
ysis showed that Gcv significantly reduced both the rate of
infection and disease, whereas Acy affected the rate of disease.
Consequently, despite the lack of viral thymidine kinase activity,
Acy is effective in vivo.
Kidney transplantation. In a prospective, randomized,
controlled study, 44 kidney transplant recipients received either
oral Gcv, 750 mg b.i.d. for 3 months postoperatively, or no
prophylaxis [34]. CMV infection occurred in 1 patient (5%)
in the Gcv group and 6 patients (27%) in the control group
( ), whereas the frequency of biopsy-proven allograft re-P ! .05
jections were 5% (1 of 21) and 18% (4 of 22), respectively.
Only 1 of these patients developed CMV disease.
Another prospective randomized, controlled trial was carried
out in 42 kidney transplant recipients who were followed for
6 months after transplantation [35]. Prophylaxis with oral Gcv
(1000 mg t.i.d.), given during the first 12 postoperative weeks,
was compared with oral Acy (200 mg b.i.d.), followed by de-
ferred therapy based on PCR results. No patients in the Gcv
group, compared with 14 of 23 patients (61%) in the deferred-
therapy group, developed CMV disease during the first 12 weeks
( ). Moreover, beyond the first 3 months, the patientsP ! .0001
in the Gcv group experienced a significantly lower frequency
and later onset of CMV disease and viremia than did the de-
ferred-therapy group. The authors concluded that an initial 12-
week course of oral Gcv prevents CMV disease and infection
in kidney transplant recipients during prophylaxis, and the ben-
efits persist after discontinuation (A-I).
Liver transplantation. The efficacy of antiviral prophylaxis
with oral Gcv the first 3 months after transplantation was in-
vestigated in a prospective randomized study of 304 liver trans-
plant recipients [36]. Oral Gcv significantly influenced the 6-
month incidence of CMV disease (4.8% vs. 18.9% in the
placebo arm), even in patients with a D/Rmatch, and even
in those patients receiving lympholytic treatment (A-I).
Heart transplantation. A large randomized, double-blind,
placebo-controlled trial has been conducted in 149 heart trans-
plant recipients [37]. Intravenous Gcv (5 mg/kg b.i.d.) was
given from postoperative day 1 through day 14, then at a dose
of 6 mg/kg daily for 5 days per week until day 28. CMV disease
occurred in 26 of 56 (46%) seropositive patients given placebo,
as compared with 5 of 56 (9%) patients treated with Gcv
( ). Whereas more of the Gcv-treated patients had mild,P ! .001
transient elevation of serum creatinine concentrations (18% vs.
4%), the incidence of neutropenia was similar in both groups.
One patient in the Gcv group died of sepsis, but the authors
did not mention whether there were any catheter-related prob-
lems (A-I).
Lung transplantation. In one of the earlier lung transplant
studies on CMV prophylaxis, 25 allograft recipients received Gcv
during the first 3 postoperative weeks and were then randomized
to either Gcv, 5 mg/kg daily 5 days/week, or Acy, 800 mg q.i.d.
until day 90 [38]. Compared with the Acy group, the cumulative
incidence of all CMV infections in the Gcv group was lower
(15% vs. 75%; ), as was the incidence of organ manifes-P ! .01
tations (overt CMV shedding and/or pneumonitis) (15% vs.
50%; ). Moreover, it seemed that the risk of obliterativeP ! .043
bronchiolitis during the first year after transplantation was lower
in the Gcv group (17% vs. 54%; ). Use of intravenousP ! .033
catheters for Gcv administration resulted in 4 complications
among 3 patients of the Gcv group (23%) (A-I).
The efficacy, tolerance, and cost-effectiveness of Gcv pro-
phylaxis after lung transplantation were evaluated in an open,
comparative study in 22 patients [39]. Intravenous Gcv (5 mg/
kg b.i.d. for 14 days), followed by either iv Gcv (5 mg/kg daily;
) or oral Gcv (1000 mg t.i.d.; ), was given up tonp 5 np 9
90 days. Thereafter, oral Gcv was continued until prednisone
was tapered below 15 mg/day. Prophylaxed groups were com-
pared with a historical control ( ) with respect to CMVnp 8
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Table 1. Management of cytomegalovirus (CMV) infection, according to type
of solid-organ transplantation and established risk factors.
Kidney transplant
Liver/heart/pancreas
transplant
Lung/bowel
transplant
No ALA ALA used No ALA ALA used No ALA ALA used
R 1 2 3 (or 2) 3 (or 2) 3 3
D/R 3 (or 2) 3 (or 2) 3 3 3, 4 3, 4
NOTE. ALA, antilymphocytic antibodies; Gcv, ganciclovir; qPCR, quantitative polymerase
chain reaction; R, recipient seropositive for CMV; D/R, donor seropositive and recipient
seronegative for CMV; 1, treatment with iv Gcv in case of CMV disease, given for 2–3 weeks
or until results of a surveillance technique such as tests for antigenemia or qPCR are repeatedly
negative; 2, preemptive use of iv Gcv, given for 2–3 weeks or until results of a surveillance
technique such as tests for antigenemia or qPCR are repeatedly negative, or while ALA is
administered; 3, prophylaxis with oral Gcv (1000 mg t.i.d.) during the first 3 months after
transplantation (3 months is chosen on the basis of data from the literature and the fact that
the risk of acute rejection generally decreases after 3 months); 4, anti-CMV hyperimmuno-
globulins. In case of CMV relapse after cessation of antiviral therapy, Gcv should be reinstituted
in accordance with hospital practice. Foscarnet should be administered if the patient does
not respond to Gcv.
disease, in-hospital stay, overall costs, and survival. Follow-up
times and the net state of immunosuppressive therapy between
groups were comparable. Six (75%) of the nonprophylaxed
patients developed CMV disease, compared with 0 in the iv
and 1 in the oral Gcv group ( ). The nonprophylaxedPp .013
patients had a longer CMV-related in-hospital stay ( )Pp .018
and insignificantly higher CMV-related costs. Bronchiolitis ob-
literans syndrome was less frequent with prophylaxis (Pp
), and the survival rate tended to be higher ( )..039 Pp .072
The only adverse effect was a subclavian vein thrombosis in
the iv Gcv group (A-II).
PREEMPTIVE TREATMENT
In 2 studies, the efficacy of preemptive Gcv therapy after kidney
transplantation was evaluated [40, 41]. Intravenous Gcv (vs.
no antiviral therapy), given during the period of treatment with
antilymphocyte antibodies, was shown to significantly reduce
the rate of CMV disease (from 33% to 14%) and viremia (from
35% to 17%) (A-I).
With use of detection of CMV antigenemia with a predefined
level of 50 CMV-pp65-positive polymorphonuclear leukocytes/
polymorphonuclear leukocytes as the surveillance tool,52 10
iv Gcv (10 mg/kg/day) prevented CMV disease in 19 heart or
lung transplant recipients, as compared with 5 cases of CMV
disease in 18 historic controls [42]. The onset of high-level
antigenemia in the latter group, however, was 2 weeks earlier
(B-II).
SUMMARY OF RECOMMENDATIONS
A scheme for CMV management after organ transplanta-
tion—stratified according to established risk factors (see above)
and based on or extrapolated from published data—was elab-
orated by the consensus panel (categories A-I and A-II, re-
spectively). The results are shown in table 1.
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